TY - JOUR
T1 - Hepatitis delta
T2 - in vitro evaluation of cytotoxicity and cytokines involved in PEG-IFN therapy
AU - Deadame de Figueiredo Nicolete, Larissa
AU - Vladimiro Cunha, Celso
AU - Paulo Tavanez, João
AU - Tomazini Pinto, Mariana
AU - Strazza Rodrigues, Evandra
AU - Kashima, Simone
AU - Tadeu Covas, Dimas
AU - Miguel Villalobos-Salcedo, Juan
AU - Nicolete, Roberto
PY - 2021/1/1
Y1 - 2021/1/1
N2 - The treatment for hepatitis Delta virus (HDV) still consists of Pegylated interferon (PEG-IFN) combined with inhibitors of Hepatitis B virus (HBV) replication. In some patients may be occur a virological response, which means a negative HDV RNA 6 months after stopping treatment. In this study it was conducted an in vitro approach with the aim to mimic possible immunological events that are observed in patients responding to PEG-IFN therapy. Jurkat cells (human T lymphocyte cell line) were employed alone or co-cultured with THP-1 (human monocytic cell line) and stimulated with controls and HBV Surface Antigen (HBsAg), Small-Delta Antigen (SHDAg), and HBsAg + SHDAg combined. Twenty-four hours stimulation with SHDAg and/or HBSAg led to a toxic profile in a co-culture condition and cell supernatants were collected for cytokines quantification. PEG-IFN was added and cells were incubated for additional 24 h. Co-cultured cells incubated with the association (SHDAg + PEG-IFN) significantly produced levels of IFN-γ, IL-2 and IL-12. On the other hand, the HBsAg alone was able to inhibit the production of IFN-γ, suggesting that this antigen may hinder the treatment exclusively with PEG-IFN.
AB - The treatment for hepatitis Delta virus (HDV) still consists of Pegylated interferon (PEG-IFN) combined with inhibitors of Hepatitis B virus (HBV) replication. In some patients may be occur a virological response, which means a negative HDV RNA 6 months after stopping treatment. In this study it was conducted an in vitro approach with the aim to mimic possible immunological events that are observed in patients responding to PEG-IFN therapy. Jurkat cells (human T lymphocyte cell line) were employed alone or co-cultured with THP-1 (human monocytic cell line) and stimulated with controls and HBV Surface Antigen (HBsAg), Small-Delta Antigen (SHDAg), and HBsAg + SHDAg combined. Twenty-four hours stimulation with SHDAg and/or HBSAg led to a toxic profile in a co-culture condition and cell supernatants were collected for cytokines quantification. PEG-IFN was added and cells were incubated for additional 24 h. Co-cultured cells incubated with the association (SHDAg + PEG-IFN) significantly produced levels of IFN-γ, IL-2 and IL-12. On the other hand, the HBsAg alone was able to inhibit the production of IFN-γ, suggesting that this antigen may hinder the treatment exclusively with PEG-IFN.
KW - Cytokines
KW - HBV
KW - HDV
KW - PEG-IFN
UR - http://www.scopus.com/inward/record.url?scp=85098712991&partnerID=8YFLogxK
UR - https://www.sciencedirect.com/science/article/pii/S1567576920337693?via%3Dihub
U2 - 10.1016/j.intimp.2020.107302
DO - 10.1016/j.intimp.2020.107302
M3 - Article
C2 - 33395584
AN - SCOPUS:85098712991
VL - 91
JO - International Immunopharmacology
JF - International Immunopharmacology
SN - 1567-5769
M1 - 107302
ER -
